A Phase II Efficacy and Safety, Open-Label, Multicenter Study of Imprime PGG Injection in Combination With Cetuximab in Patients With Stage IV KRAS-Mutant Colorectal Cancer

Clinical Colorectal Cancer

Volumn 15, Issue 3, 2016, Pages 222-227

  Segal, Neil H ^a   Gada, Purvi ^b   Senzer, Neil ^c   Gargano, Michele A ^d   Patchen, Myra L ^d   Saltz, Leonard B ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c Mary Crowley Cancer Research Centers   (United States)

^d Biothera   (United States)

Author keywords

Antibody; Complement; Epidermal growth factor receptor; Immune; glucan

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; CETUXIMAB; IMPRIME PGG; UNCLASSIFIED DRUG; EPIGLUCAN; GLUCAN; KRAS PROTEIN, HUMAN; PROTEIN P21;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTINEOPLASTIC ACTIVITY; APPLICATION SITE REACTION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER STAGING; CANCER SURVIVAL; CHILL; CLINICAL ARTICLE; COLORECTAL CANCER; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HYPOMAGNESEMIA; INFLAMMATION; MALE; MUTANT; NAUSEA; ONCOGENE K RAS; OPEN STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; SIDE EFFECT; STOMATITIS; TACHYCARDIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; ADVERSE EFFECTS; CLINICAL TRIAL; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; GENETICS; IMMUNOTHERAPY; KAPLAN MEIER METHOD; MIDDLE AGED; MULTICENTER STUDY; MUTATION; PATHOLOGY; PROCEDURES; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GLUCANS; HUMANS; IMMUNOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84960156170     PISSN: 15330028     EISSN: 19380674     Source Type: Journal    
DOI: 10.1016/j.clcc.2016.02.013     Document Type: Article

References (23)

1. 1 Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2012. CA Cancer J Clin 62 (2012), 10–29.
2. 2 Cutsem, E.V., Lang, I., Folprecht, G., et al. Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): the influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. ASCO Gastrointestinal Cancers Symposium, 2010 (abstract 281).
3. 3 De Roock, W., De Schutter, J., De Hertogh, G., et al. KRAS mutations preclude tumor shrinkage of colorectal cancers treated with cetuximab ASCO annual meeting (abstract 4132). J Clin Oncol, 25, 2007.
4. 4 Bokemeyer, C., Kohne, C.H., Ciardiello, F., et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 51 (2015), 1243–1252.
5. 5 Brown, G.D., Gordon, S., Immune recognition of fungal beta-glucans. Cell Microbiol 7 (2005), 471–479.
6. 6 Cain, J.A., Newman, S.L., Ross, G.D., Role of complement receptor type three and serum opsonins in the neutrophil response to yeast. Complement 4 (1987), 75–86.
7. 7 Vetvicka, V., Thornton, B.P., Ross, G.D., Soluble beta-glucan polysaccharide binding to the lectin site of neutrophil or natural killer cell complement receptor type 3 (CD11b/CD18) generates a primed state of the receptor capable of mediating cytotoxicity of iC3b-opsonized target cells. J Clin Invest 98 (1996), 50–61.
8. 8 Xia, Y., Vetvicka, V., Yan, J., Hanikyrova, M., Mayadas, T., Ross, G.D., The beta-glucan-binding lectin site of mouse CR3 (CD11b/CD18) and its function in generating a primed state of the receptor that mediates cytotoxic activation in response to iC3b-opsonized target cells. J Immunol 162 (1999), 2281–2290.
9. 9 Qi, C., Cai, Y., Gunn, L., et al. Differential pathways regulating innate and adaptive antitumor immune responses by particulate and soluble yeast-derived beta-glucans. Blood 117 (2011), 6825–6836.
10. 10 Li, B., Allendorf, D.J., Hansen, R., et al. Yeast beta-glucan amplifies phagocyte killing of iC3b-opsonized tumor cells via complement receptor 3-Syk-phosphatidylinositol 3-kinase pathway. J Immunol 177 (2006), 1661–1669.
11. 11 Li, B., Allendorf, D.J., Hansen, R., et al. Combined yeast β-glucan and antitumor monoclonal antibody therapy requires C5a-mediated neutrophil chemotaxis via regulation of decay-accelerating factor CD55. Cancer Res 67 (2007), 7421–7430.
12. 12 Chan AS, Qiu X, Jonas A, Kangas T, Ottoson NR, Bose N. Imprime PGG modulates the function of monocyte-derived M2 macrophages and dendritic cells to drive T-cell expansion. Presented at the Annual Meeting of the American Association of Cancer Research, Philadelphia, PA, April 18-22, 2015.
13. 13 Bose N, Chan AS, Jonas A, Qiu X, Ottoson NR. Imprime PGG treatment elicits a coordinated antitumor immune response that triggers enhanced expression of PD-L1 on tumor cells as well as monocyte-derived macrophages and dendritic cells. Presented at the Annual Meeting of the American Association of Cancer Research, Philadelphia, PA, April 18-22, 2015.
14. 14 Hsu, Y.F., Ajona, D., Corrales, L., et al. Complement activation mediates cetuximab inhibition of non–small-cell lung cancer tumor growth in vivo. Mol Cancer, 9, 2010, 139.
15. 15 Milano, G., Etienne-Grimaldi, M.C., Dahan, L., et al. Epidermal growth factor receptor (EGFR) status and K-Ras mutations in colorectal cancer. Ann Oncol 19 (2008), 2033–2038.
16. 16 Chen, T.T., Ng, T.H., Optimal flexible designs in phase II clinical trials. Stat Med 17 (1998), 2301–2312.
17. 17 Karapetis, C.S., Khambata-Ford, S., Jonker, D.J., et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 359 (2008), 1757–1765.
18. 18 Freeman, D.J., Juan, T., Reiner, M., et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 7 (2008), 184–190.
19. 19 Amado, R.G., Wolf, M., Peeters, M., et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26 (2008), 1626–1634.
20. 20 Price TJ, Peeters M, Kim T, Li J, Cascinu S, Ruff P. ASPECCT: a randomized, multicenter, open-label, phase 3 study of panitumumab (pmab) vs cetuximab (cmab) for previously treated wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Presented at the European Cancer Congress, Amsterdam, The Netherlands, Sep 27-Oct 01, 2013.
21. 21 Mao, C., Huang, Y.F., Yang, Z.Y., Zheng, D.Y., Chen, J.Z., Tang, J.L., KRAS p.G13D mutation and codon 12 mutations are not created equal in predicting clinical outcomes of cetuximab in metastatic colorectal cancer: a systematic review and meta-analysis. Cancer 119 (2013), 714–721.
22. 22 Nakadate, Y., Kodera, Y., Kitamura, Y., et al. KRAS mutation confers resistance to antibody-dependent cellular cytotoxicity of cetuximab against human colorectal cancer cells. Int J Cancer 134 (2013), 2146–2155.
23. 23 Kohrt, H.E., Colevas, A.D., Houot, R., et al. CD137 Activation augments the efficacy of EGFR-targeted therapy. J Clin Invest 124 (2014), 2668–2682.